EUVIMEDEUVIMED entdecken
Open Access

Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

Irene Peris iD, Silvia Romero-Murillo iD, Elena Martínez-Balsalobre iD, Caroline C Farrington iD, Elena Arriazu iD, Nerea Marcotegui, Marta Jiménez-Muñoz iD, Cristina Alburquerque-Prieto iD, Andrea Torres-López, Vicente Fresquet iD, Jose A Martínez-Climent iD, Maria C Mateos und 4 weitere

Blood · 2023

DOI: 10.1182/blood.2022016466 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Irene Peris und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Médica Aplicada, University of Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Protein Phosphatase 2, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax combination therapies are becoming the standard of care in acute myeloid leukemia (AML). However, the therapeutic benefit of these drugs in older/unfit patients is limited to only a few months, highlighting the need for more effective therapies. Protein phosphatase 2A (PP2A) is a tumor suppressor phosphatase with pleiotropic functions that becomes inactivated in ∼70% of AML cases. PP2A promotes cancer cell death by modulating the phosphorylation state in a variety of proteins along the mitochondrial apoptotic pathway. We therefore hypothesized that pharmacological PP2A reactivation could increase BCL2 dependency in AML cells and, thus, potentiate venetoclax–induced cell death. Here, by using 3 structurally distinct PP2A-activating drugs, we show that PP2A reactivation synergistically enhances venetoclax activity in AML cell lines, primary cells, and xenograft models. Through the use of gene editing tools and pharmacological approaches, we demonstrate that the observed therapeutic synergy relies on PP2A complexes containing the B56α regulatory subunit, of which expression dictates response to the combination therapy. Mechanistically, PP2A reactivation enhances venetoclax-driven apoptosis through simultaneous inhibition of antiapoptotic BCL2 and extracellular signal-regulated kinase signaling, with the latter decreasing MCL1 protein stability. Finally, PP2A targeting increases the efficacy of the clinically approved venetoclax and azacitidine combination in vitro, in primary cells, and in an AML patient-derived xenograft model. These preclinical results provide a scientific rationale for testing PP2A-activating drugs with venetoclax combinations in AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Phosphatase 2Leukemia, Myeloid, AcuteHumansAgedMyeloid Cell Leukemia Sequence 1 ProteinCell Line, TumorProto-Oncogene Proteins c-bcl-2Bridged Bicyclo Compounds, HeterocyclicApoptosisSulfonamides

Substanzen

Myeloid Cell Leukemia Sequence 1 ProteinProtein Phosphatase 2Proto-Oncogene Proteins c-bcl-2Bridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamidesMCL1 protein, humanPP2A-B56alpha protein, humanBCL2 protein, human

Autor:innen und Institutionen

  • Centro de Investigación Médica Aplicada, University of Navarra, Pamplona, Spain.
  • Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain.
  • Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
  • Cancer and Aging Group, Hospital Universitario Virgen de la Arrixaca, and Instituto Murciano de Investigación Biosanitaria, Murcia, Spain.
  • Division of Genetic Medicine, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI.
  • Centro de Investigación Biomédica en Red de Oncología, Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Irene Peris, Silvia Romero-Murillo, Elena Martínez-Balsalobre, Caroline C Farrington, Elena Arriazu, Marta Jiménez-Muñoz, Cristina Alburquerque-Prieto, Vicente Fresquet, Jose A Martínez-Climent, Maria L Cayuela, Goutham Narla, Maria D Odero, Carmen Vicente

Förderung

  • NCI NIH HHS

Zitieren

APA

Peris, I., Romero-Murillo, S., Martínez-Balsalobre, E., Farrington, C. C., Arriazu, E., Marcotegui, N., Jiménez-Muñoz, M., Alburquerque-Prieto, C., Torres-López, A., Fresquet, V., Martínez-Climent, J. A., Mateos, M. C., Cayuela, M. L., Narla, G., Odero, M. D., & Vicente, C. (2023). Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation. Blood. https://doi.org/10.1182/blood.2022016466

Vancouver

Peris I, Romero-Murillo S, Martínez-Balsalobre E, Farrington CC, Arriazu E, Marcotegui N, et al. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation. Blood. 2023. doi:10.1182/blood.2022016466

BibTeX
@article{Peris2023,
  author = {Peris, Irene and Romero-Murillo, Silvia and Martínez-Balsalobre, Elena and Farrington, Caroline C and Arriazu, Elena and Marcotegui, Nerea and Jiménez-Muñoz, Marta and Alburquerque-Prieto, Cristina and Torres-López, Andrea and Fresquet, Vicente and Martínez-Climent, Jose A and Mateos, Maria C and Cayuela, Maria L and Narla, Goutham and Odero, Maria D and Vicente, Carmen},
  title = {Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022016466}
}
Kostenlos starten →